Review





Similar Products

90
EUROIMMUN autoimmune cerebellar ataxia antibody panel [tr(dner)/ itpr1/homer-3/ncdn/mglur1/septin complex/sez6l2/glurd2 /ap3b2 antibodies]
Autoimmune Cerebellar Ataxia Antibody Panel [Tr(Dner)/ Itpr1/Homer 3/Ncdn/Mglur1/Septin Complex/Sez6l2/Glurd2 /Ap3b2 Antibodies], supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/autoimmune cerebellar ataxia antibody panel [tr(dner)/ itpr1/homer-3/ncdn/mglur1/septin complex/sez6l2/glurd2 /ap3b2 antibodies]/product/EUROIMMUN
Average 90 stars, based on 1 article reviews
autoimmune cerebellar ataxia antibody panel [tr(dner)/ itpr1/homer-3/ncdn/mglur1/septin complex/sez6l2/glurd2 /ap3b2 antibodies] - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
EUROIMMUN autoimmune cerebellar ataxia antibody panel [tr(dner)/ itpr1/homer-3/ncdn/mglur1/septin complex/sez6l2/ glurd2/ap3b2 antibodies]
Autoimmune Cerebellar Ataxia Antibody Panel [Tr(Dner)/ Itpr1/Homer 3/Ncdn/Mglur1/Septin Complex/Sez6l2/ Glurd2/Ap3b2 Antibodies], supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/autoimmune cerebellar ataxia antibody panel [tr(dner)/ itpr1/homer-3/ncdn/mglur1/septin complex/sez6l2/ glurd2/ap3b2 antibodies]/product/EUROIMMUN
Average 90 stars, based on 1 article reviews
autoimmune cerebellar ataxia antibody panel [tr(dner)/ itpr1/homer-3/ncdn/mglur1/septin complex/sez6l2/ glurd2/ap3b2 antibodies] - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
EUROIMMUN detection of anti-dner
Detection Of Anti Dner, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/detection of anti-dner/product/EUROIMMUN
Average 90 stars, based on 1 article reviews
detection of anti-dner - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

92
Proteintech dner
Figure 2. Discovery process and preliminary validation of candidate markers for postoperative recurrence in LAGC patients based on public databases and transcriptomics sequencing data. A) Four candidate <t>mRNAs</t> <t>(AGTR1,</t> <t>DNER,</t> EPHA7, SUSD5) were identified through a Venn diagram analysis using the TCGA database (28 recurrent patients versus 159 non-recurrent patients), transcriptome data from the GEO database (125 recurrent patients versus 157 non-recurrent patients), and paired mRNA sequencing (3 recurrent patients versus 3 non-recurrent patients). B) A volcano plot illustrates the expression levels of these four genes in recurrent and non-recurrent cancer tissues. C) The expression levels of the four candidate mRNAs (AGTR1,
Dner, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dner/product/Proteintech
Average 92 stars, based on 1 article reviews
dner - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

90
EUROIMMUN anti-dner
Figure 2. Discovery process and preliminary validation of candidate markers for postoperative recurrence in LAGC patients based on public databases and transcriptomics sequencing data. A) Four candidate <t>mRNAs</t> <t>(AGTR1,</t> <t>DNER,</t> EPHA7, SUSD5) were identified through a Venn diagram analysis using the TCGA database (28 recurrent patients versus 159 non-recurrent patients), transcriptome data from the GEO database (125 recurrent patients versus 157 non-recurrent patients), and paired mRNA sequencing (3 recurrent patients versus 3 non-recurrent patients). B) A volcano plot illustrates the expression levels of these four genes in recurrent and non-recurrent cancer tissues. C) The expression levels of the four candidate mRNAs (AGTR1,
Anti Dner, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-dner/product/EUROIMMUN
Average 90 stars, based on 1 article reviews
anti-dner - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Deltex Medical dner/deltex signaling
Figure 2. Discovery process and preliminary validation of candidate markers for postoperative recurrence in LAGC patients based on public databases and transcriptomics sequencing data. A) Four candidate <t>mRNAs</t> <t>(AGTR1,</t> <t>DNER,</t> EPHA7, SUSD5) were identified through a Venn diagram analysis using the TCGA database (28 recurrent patients versus 159 non-recurrent patients), transcriptome data from the GEO database (125 recurrent patients versus 157 non-recurrent patients), and paired mRNA sequencing (3 recurrent patients versus 3 non-recurrent patients). B) A volcano plot illustrates the expression levels of these four genes in recurrent and non-recurrent cancer tissues. C) The expression levels of the four candidate mRNAs (AGTR1,
Dner/Deltex Signaling, supplied by Deltex Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dner/deltex signaling/product/Deltex Medical
Average 90 stars, based on 1 article reviews
dner/deltex signaling - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
EUROIMMUN autoimmune cerebellar ataxia antibody panel [anti-tr(dner)/zic4/itpr1/ homer-3/ ncdn/pkcγ/pca-2/ap3b2/mglur1/ atp1a3 antibodies]
Figure 2. Discovery process and preliminary validation of candidate markers for postoperative recurrence in LAGC patients based on public databases and transcriptomics sequencing data. A) Four candidate <t>mRNAs</t> <t>(AGTR1,</t> <t>DNER,</t> EPHA7, SUSD5) were identified through a Venn diagram analysis using the TCGA database (28 recurrent patients versus 159 non-recurrent patients), transcriptome data from the GEO database (125 recurrent patients versus 157 non-recurrent patients), and paired mRNA sequencing (3 recurrent patients versus 3 non-recurrent patients). B) A volcano plot illustrates the expression levels of these four genes in recurrent and non-recurrent cancer tissues. C) The expression levels of the four candidate mRNAs (AGTR1,
Autoimmune Cerebellar Ataxia Antibody Panel [Anti Tr(Dner)/Zic4/Itpr1/ Homer 3/ Ncdn/Pkcγ/Pca 2/Ap3b2/Mglur1/ Atp1a3 Antibodies], supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/autoimmune cerebellar ataxia antibody panel [anti-tr(dner)/zic4/itpr1/ homer-3/ ncdn/pkcγ/pca-2/ap3b2/mglur1/ atp1a3 antibodies]/product/EUROIMMUN
Average 90 stars, based on 1 article reviews
autoimmune cerebellar ataxia antibody panel [anti-tr(dner)/zic4/itpr1/ homer-3/ ncdn/pkcγ/pca-2/ap3b2/mglur1/ atp1a3 antibodies] - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
EUROIMMUN detection of anti- dner
Figure 2. Discovery process and preliminary validation of candidate markers for postoperative recurrence in LAGC patients based on public databases and transcriptomics sequencing data. A) Four candidate <t>mRNAs</t> <t>(AGTR1,</t> <t>DNER,</t> EPHA7, SUSD5) were identified through a Venn diagram analysis using the TCGA database (28 recurrent patients versus 159 non-recurrent patients), transcriptome data from the GEO database (125 recurrent patients versus 157 non-recurrent patients), and paired mRNA sequencing (3 recurrent patients versus 3 non-recurrent patients). B) A volcano plot illustrates the expression levels of these four genes in recurrent and non-recurrent cancer tissues. C) The expression levels of the four candidate mRNAs (AGTR1,
Detection Of Anti Dner, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/detection of anti- dner/product/EUROIMMUN
Average 90 stars, based on 1 article reviews
detection of anti- dner - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Figure 2. Discovery process and preliminary validation of candidate markers for postoperative recurrence in LAGC patients based on public databases and transcriptomics sequencing data. A) Four candidate mRNAs (AGTR1, DNER, EPHA7, SUSD5) were identified through a Venn diagram analysis using the TCGA database (28 recurrent patients versus 159 non-recurrent patients), transcriptome data from the GEO database (125 recurrent patients versus 157 non-recurrent patients), and paired mRNA sequencing (3 recurrent patients versus 3 non-recurrent patients). B) A volcano plot illustrates the expression levels of these four genes in recurrent and non-recurrent cancer tissues. C) The expression levels of the four candidate mRNAs (AGTR1,

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Transcriptomics-Based Liquid Biopsy for Early Detection of Recurrence in Locally Advanced Gastric Cancer.

doi: 10.1002/advs.202406276

Figure Lengend Snippet: Figure 2. Discovery process and preliminary validation of candidate markers for postoperative recurrence in LAGC patients based on public databases and transcriptomics sequencing data. A) Four candidate mRNAs (AGTR1, DNER, EPHA7, SUSD5) were identified through a Venn diagram analysis using the TCGA database (28 recurrent patients versus 159 non-recurrent patients), transcriptome data from the GEO database (125 recurrent patients versus 157 non-recurrent patients), and paired mRNA sequencing (3 recurrent patients versus 3 non-recurrent patients). B) A volcano plot illustrates the expression levels of these four genes in recurrent and non-recurrent cancer tissues. C) The expression levels of the four candidate mRNAs (AGTR1,

Article Snippet: Membranes were probed with antibodies against AGTR1 (1:1000 dilutions, 25343-1-AP, Proteintech, Chicago, USA), DNER (1:1000 dilutions, 24362-1-AP, Proteintech, Chicago, USA), EPHA7 (1:1000 dilutions, 66667-1-Ig, Proteintech, Chicago, USA), SUSD5 (1:500 dilutions, bs-7331R, Bioss, Beijing, China), CREB (1:500 dilutions, 381013, Zenbio, Chengdu, China), p-CREB (1:500 dilutions, 380697, Zenbio, Chengdu, China), and GAPDH (1:10000 dilutions, 10494-1-AP, Proteintech, Chicago, USA).

Techniques: Biomarker Discovery, Sequencing, Expressing

Figure 7. Four recurrence-related mRNA genes promote GC cell proliferation, migration and invasion in vitro. A,B) Scratch assay to evaluate the migration ability of GC cells after knockdown of AGTR1 and DNER, respectively. C,D) Transwell assay to assess the invasion and metastasis abilities of GC cells after knockdown of AGTR1 and DNER, respectively. E,F) EdU assay to determine the proliferation ability of GC cells after knockdown of AGTR1 and DNER, respectively. G–J) Colony formation assay to measure the proliferation ability of GC cells after knockdown of AGTR1, DNER, EPHA7, and SUSD5. K–N) CCK-8 assay to detect the proliferation ability of GC cells after knockdown of AGTR1, DNER, EPHA7, and SUSD5. *P < 0.05, **P < 0.01, ***P < 0.001.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Transcriptomics-Based Liquid Biopsy for Early Detection of Recurrence in Locally Advanced Gastric Cancer.

doi: 10.1002/advs.202406276

Figure Lengend Snippet: Figure 7. Four recurrence-related mRNA genes promote GC cell proliferation, migration and invasion in vitro. A,B) Scratch assay to evaluate the migration ability of GC cells after knockdown of AGTR1 and DNER, respectively. C,D) Transwell assay to assess the invasion and metastasis abilities of GC cells after knockdown of AGTR1 and DNER, respectively. E,F) EdU assay to determine the proliferation ability of GC cells after knockdown of AGTR1 and DNER, respectively. G–J) Colony formation assay to measure the proliferation ability of GC cells after knockdown of AGTR1, DNER, EPHA7, and SUSD5. K–N) CCK-8 assay to detect the proliferation ability of GC cells after knockdown of AGTR1, DNER, EPHA7, and SUSD5. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Membranes were probed with antibodies against AGTR1 (1:1000 dilutions, 25343-1-AP, Proteintech, Chicago, USA), DNER (1:1000 dilutions, 24362-1-AP, Proteintech, Chicago, USA), EPHA7 (1:1000 dilutions, 66667-1-Ig, Proteintech, Chicago, USA), SUSD5 (1:500 dilutions, bs-7331R, Bioss, Beijing, China), CREB (1:500 dilutions, 381013, Zenbio, Chengdu, China), p-CREB (1:500 dilutions, 380697, Zenbio, Chengdu, China), and GAPDH (1:10000 dilutions, 10494-1-AP, Proteintech, Chicago, USA).

Techniques: Migration, In Vitro, Wound Healing Assay, Knockdown, Transwell Assay, EdU Assay, Colony Assay, CCK-8 Assay

Figure 8. Four recurrence-related mRNA genes promote GC cell xenograft tumor growth and metastasis in vivo. A–D) Morphological images showing reduced subcutaneous xenograft tumor formation in mice injected with AGS cells knocked down for AGTR1, DNER, EPHA7, and SUSD5, along with tumor volume growth curves and final tumor weights. E) Representative IHC images of subcutaneous xenograft tumors after knockdown of AGTR1 (left), and quantification of IHC staining data for Ki67, N-cadherin, E-cadherin, and Vimentin in each group of mice (right). F) Representative IHC images of peritoneal metastasis tumors after intraperitoneal injection of AGS cells knocked down for AGTR1 (left), and quantification of IHC staining data for MMP9, N-cadherin, E-cadherin, and Vimentin in each group of mice (right). G) Representative images of peritoneal metastasis tumors in the abdominal cavity of mice injected with AGS cells knocked down for AGTR1. H) Measurement and quantification of the number of peritoneal metastatic tumors in

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Transcriptomics-Based Liquid Biopsy for Early Detection of Recurrence in Locally Advanced Gastric Cancer.

doi: 10.1002/advs.202406276

Figure Lengend Snippet: Figure 8. Four recurrence-related mRNA genes promote GC cell xenograft tumor growth and metastasis in vivo. A–D) Morphological images showing reduced subcutaneous xenograft tumor formation in mice injected with AGS cells knocked down for AGTR1, DNER, EPHA7, and SUSD5, along with tumor volume growth curves and final tumor weights. E) Representative IHC images of subcutaneous xenograft tumors after knockdown of AGTR1 (left), and quantification of IHC staining data for Ki67, N-cadherin, E-cadherin, and Vimentin in each group of mice (right). F) Representative IHC images of peritoneal metastasis tumors after intraperitoneal injection of AGS cells knocked down for AGTR1 (left), and quantification of IHC staining data for MMP9, N-cadherin, E-cadherin, and Vimentin in each group of mice (right). G) Representative images of peritoneal metastasis tumors in the abdominal cavity of mice injected with AGS cells knocked down for AGTR1. H) Measurement and quantification of the number of peritoneal metastatic tumors in

Article Snippet: Membranes were probed with antibodies against AGTR1 (1:1000 dilutions, 25343-1-AP, Proteintech, Chicago, USA), DNER (1:1000 dilutions, 24362-1-AP, Proteintech, Chicago, USA), EPHA7 (1:1000 dilutions, 66667-1-Ig, Proteintech, Chicago, USA), SUSD5 (1:500 dilutions, bs-7331R, Bioss, Beijing, China), CREB (1:500 dilutions, 381013, Zenbio, Chengdu, China), p-CREB (1:500 dilutions, 380697, Zenbio, Chengdu, China), and GAPDH (1:10000 dilutions, 10494-1-AP, Proteintech, Chicago, USA).

Techniques: In Vivo, Injection, Knockdown, Immunohistochemistry